advertisement
Acorda Therapeutics upgraded to "outperform"
09/07/10 - Robert W. Baird
NEW YORK, September 7 (newratings.com) - Analysts at Robert W Baird upgrade Acorda Therapeutics Inc (ACOR) from "neutral" to "outperform." The target price is set to $40.
Share Recommend this article to a friend
add ACOR to my stocks and get e-mail alerts on Acorda Therapeutics Inc.
News